Wegovy and Progesterone HRT Interaction: What Patients and Clinicians Need to Know

Wegovy contains semaglutide 2.4 mg and is injected once weekly. It is a GLP-1 (glucagon-like peptide-1) receptor agonist that the FDA has approved for chronic weight management in adults who have obesity or are overweight with an obesity-related condition. Ozempic, which contains semaglutide 2 mg and is used for type 2 diabetes, is the same active ingredient as Wegovy, though Wegovy uses a higher maintenance dose. This article focuses on Wegovy and does not cover compounded semaglutide products. Compounded versions are not FDA-approved and may have different quality standards and dosing concerns.

Progesterone HRT here refers to progestogen therapy given alongside estrogen for menopausal hormone replacement, most often oral micronized progesterone (for example, Prometrium), and sometimes vaginal or transdermal formulations. This is distinct from progestin-only contraceptives, though some of the same absorption logic applies to them.

The direct answer

Wegovy has no known interaction with progesterone through the cytochrome P450 enzyme system: semaglutide is a peptide, not a small molecule, and is not metabolized by or known to inhibit or induce CYP enzymes. The interaction that matters is indirect and mechanical. Semaglutide slows gastric emptying, and oral progesterone's absorption depends on gastric transit time, so oral (not vaginal or transdermal) progesterone is the formulation at theoretical risk of altered absorption. No dedicated clinical trial has tested semaglutide plus progesterone HRT directly, so the guidance below rests on mechanistic pharmacology and general prescribing caution rather than trial-confirmed outcomes, and that gap should shape how much weight any single recommendation carries.

Why this combination is not automatically a problem

The combination is not listed as contraindicated in either drug's FDA labeling. Standard drug-interaction references typically flag it as a moderate-severity interaction, meaning it is worth a management plan rather than avoidance. Two separate mechanisms are involved, and they do not depend on each other:

1. A pharmacokinetic effect: semaglutide-related delayed gastric emptying may slow or reduce absorption of oral progesterone.
2. A pharmacodynamic effect: progesterone's active metabolite is sedating, and this can add to the fatigue and malaise some patients feel during semaglutide dose escalation.

A patient can experience either effect, both, or neither. Nausea and fatigue from semaglutide are most common during the first weeks of a dose increase and tend to lessen as the body adjusts, though the underlying gastric-emptying delay does not fully disappear while a patient stays on the medication.

Mechanism 1: gastric emptying and oral progesterone absorption

GLP-1 receptor agonists, including semaglutide, are well established in the pharmacology literature to slow gastric emptying through GLP-1 receptors in the gut and vagal signaling pathways. The Wegovy prescribing information includes a general caution that delayed gastric emptying may affect the absorption of orally administered medications and advises monitoring accordingly. This is a class-level statement rather than a progesterone-specific one; progesterone is not named in the label.

Oral micronized progesterone undergoes substantial first-pass metabolism in the liver and gut wall, and its absorption is sensitive to how quickly it transits the stomach and reaches the small intestine. In principle, slower gastric emptying could delay the time to peak concentration and modestly lower peak concentration, even if total drug exposure over time changes less. Published pharmacokinetic data quantifying this specific interaction between semaglutide and oral progesterone were not available in the sources reviewed for this article, and any precise percentage reduction in absorption should be treated as unverified until a dedicated study is located. What can be stated with more confidence is the direction of the effect and the mechanism behind it.

Vaginal and transdermal progesterone routes bypass gastric transit almost entirely, so this pharmacokinetic concern does not meaningfully apply to them.

Mechanism 2: sedation overlap

Oral progesterone is metabolized to allopregnanolone, a neurosteroid that acts on GABA-A receptors, the same receptor complex targeted by benzodiazepines and alcohol. This is why oral progesterone commonly causes drowsiness, and why bedtime dosing is a standard recommendation regardless of what else a patient is taking.

Semaglutide is not sedating by a shared mechanism, but the nausea, low appetite, and general malaise reported during dose escalation can feel similar to a patient, and the two effects can layer. A patient starting both medications around the same time, or increasing semaglutide dose while also on a higher oral progesterone dose, is the scenario most likely to notice combined fatigue or dizziness.

What is established, what is plausible, and what is not established

Established: Semaglutide slows gastric emptying (a labeled, well-documented pharmacologic effect of the drug class). Oral progesterone causes CNS sedation through allopregnanolone (well-documented neurosteroid pharmacology). Semaglutide is not a CYP substrate, inhibitor, or inducer, so there is no direct enzyme-mediated interaction with progesterone.

Plausible but not directly demonstrated: That semaglutide-related gastric slowing meaningfully lowers oral progesterone's peak concentration in a way that could affect endometrial protection. That combined fatigue from both drugs is clinically significant for most patients rather than a minor, self-limited nuisance during dose escalation.

Not established: The magnitude of any absorption change (no verified pharmacokinetic study of this specific pairing was identified). Any specific serum progesterone threshold that should trigger a formulation switch. Whether outcomes differ between patients who start Wegovy first versus progesterone first.

Readers and clinicians should treat any source that states a precise percentage change in progesterone absorption from semaglutide co-administration with caution unless it links to a specific pharmacokinetic study of that pairing, because no such study was confirmed in preparing this article.

Evidence-status interaction assessment

Use this to decide how much monitoring a given patient realistically needs, and to have a focused conversation with a prescriber or pharmacist rather than a general one.

What the FDA labels address, and what they do not

The Wegovy label discusses delayed gastric emptying and general caution around co-administered oral medications, without naming progesterone specifically. The Prometrium (oral micronized progesterone) label notes sedation as a known effect and recommends bedtime dosing for that reason, independent of any GLP-1 agonist use. Neither label addresses the other drug directly, because that co-prescribing scenario is not something either label was written to cover. Readers who want the exact current wording should check the FDA labels directly, since label language is periodically revised:

• Wegovy (semaglutide) prescribing information, FDA (consult the current FDA label directly, as the specific link could not be verified)
• Prometrium (progesterone) prescribing information, FDA (consult the current FDA label directly, as the specific link could not be verified)

Specialty guidance on menopausal hormone therapy generally supports the idea that route of administration affects progesterone's systemic and CNS exposure, with vaginal and transdermal routes producing less first-pass metabolism than oral dosing. Readers should check the current position statement from a menopause-focused professional society for the exact, up-to-date wording rather than relying on a paraphrase here.

Formulation choices in practice

Oral micronized progesterone carries the most exposure to the absorption question above. Bedtime dosing is already standard practice for sedation, and separating the dose from a large, high-fat meal may reduce additional gastric-transit slowing, though this has not been studied specifically in semaglutide users.

Vaginal progesterone (used off-label vaginally, or as a dedicated vaginal product) reaches the uterus with less dependence on gastric transit and lower systemic exposure at equivalent endometrial-protective doses. It sidesteps the semaglutide-specific absorption concern, though it requires a different administration routine that not every patient prefers.

Transdermal progesterone creams are commonly marketed but the evidence supporting adequate endometrial protection through this route, independent of any GLP-1 interaction, is weaker and more contested than for oral or vaginal progesterone. Switching to a transdermal cream purely to avoid a semaglutide interaction, without confirming adequate endometrial protection, is not a safe substitution on its own.

Monitoring and what to report

There is no validated serum progesterone target that confirms adequate endometrial protection specifically in patients also taking semaglutide. In practice, monitoring is symptom-driven:

• Return of vasomotor symptoms (hot flashes, night sweats) that had previously been controlled by HRT
• Any new abnormal uterine bleeding
• New or worsening dizziness, drowsiness, or cognitive fogginess in the hours after an oral progesterone dose, particularly during the first weeks of a semaglutide dose increase

A clinician may choose to check a serum progesterone level if any of the above occur, but this should be interpreted as one data point in a clinical decision rather than a number with an established safe cutoff for this scenario.

Questions worth raising with a prescriber or pharmacist

• Given my current progesterone dose and route, does gastric-emptying delay from semaglutide change your recommendation?
• If my hot flashes or bleeding pattern changes after starting Wegovy, would you check a progesterone level or switch my formulation first?
• Is there a reason to prefer starting semaglutide before or after adjusting my HRT route, rather than doing both at once?
• If I already take another CNS-active medication (a sleep aid, antihistamine, or anti-anxiety medication), does that change the calculus here?

Special situations worth naming

Post-hysterectomy patients on estrogen-only HRT do not need progesterone for endometrial protection, so this interaction is not relevant unless progesterone is being used off-label for another reason such as sleep.

Perimenopausal patients using cyclic progesterone (roughly 10 to 14 days per month) concentrate the sedation and absorption concerns into those days, while the gastric-emptying effect from semaglutide is present continuously. A route switch for just part of the month may be more practical for this group than for someone on continuous progesterone.

Patients also on another CNS-active medication (sedating antihistamines, low-dose tricyclics, anxiolytics) may notice combined sedation more, and this is worth flagging specifically rather than assuming any drowsiness is from Wegovy alone.

When to seek urgent care rather than wait for a routine visit

New, unexplained heavy vaginal bleeding, severe abdominal pain, signs of an allergic reaction, or significant confusion or fainting are not expected effects of this combination and warrant prompt medical attention rather than a wait-and-see approach. Persistent nausea and vomiting that prevent keeping fluids down during semaglutide dose escalation also warrant contacting a prescriber promptly, since dehydration and medication effects can compound each other.

References

1. US Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. NDA 215256. (Link could not be verified and has been removed; consult the current FDA label directly.)
2. US Food and Drug Administration. Prometrium (progesterone, USP) capsules prescribing information. NDA 019781. (Link could not be verified and has been removed; consult the current FDA label directly.)

A note on sourcing: earlier versions of interaction pages in this series cited specific PubMed identifiers and quoted guideline language for numeric claims about absorption changes and trial outcomes. Those identifiers could not be verified against the papers they were meant to support, so they have been removed rather than left in place with a wrong citation attached. Claims that could not be traced to a verifiable primary source are stated here in general, hedged terms and flagged for confirmation during medical review.